Navigation Links
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Date:10/20/2011

>

8.3.7 Annual Cost of Therapy 47

8.3.8 Primary Research 47

8.3.9 Expert Panels 47

8.4 Contact Us 48

8.5 Disclaimer 48

8.6 Sources 48

1.1 List of Tables

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5

Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Table 3: Five-Year Relative Survival Rates, By Stages 14

Table 4: Approval Status of Afinitor 30

Table 5: Drug Risk Benefit Score of Afinitor 31

Table 6: Annual Cost of Therapy of Afinitor 34

Table 7: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 2013–2020 35

Table 8: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 2013–2020 36

Table 9: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 2013–2020 37

Table 10: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 2013–2020 38

Table 11: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 2013–2020 39

Table 12: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 2013–2020 40

Table 13: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 2013–2020 41

Table 14: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013–2020 42

1.2 List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6

Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 8

Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9

Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10

Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10

Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11

Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11

Figure 8: Mortality per 100,000, Breast Cance
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. FDA Approves New Indication for Afinitor
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
11. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has announced ... Global Trends, Estimates and Forecasts, 2012-2018" report to ... Global Electrocardiogram Devices (ECG) sector is projected ... North America accounts for nearly 36% (2015) ... claims approximately 27% (2018). Asia-Pacific ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... Amgen Inc. (Nasdaq: AMGN ),today released ... of,the long-term safety and efficacy of Nplate(TM) (romiplostim) ... Chronic ITP is a,chronic and serious autoimmune disorder ... blood, sometimes leading to serious bleeding events.,The results ...
... BEACH, California and AMSTERDAM, December 8 ,Agendia, a ... that,leading Agendia and the Netherlands Cancer Institute researchers ... San Antonio Breast Cancer Symposium,(SABCS) and Agendia will ... Individualized Breast Cancer Therapy symposium. The San Antonio,Breast ...
Cached Medicine Technology:Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 2Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 3Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 4Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 5Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 6Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 7Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 8Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 9Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 10Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 11Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients 12Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
(Date:12/19/2014)... December 19, 2014 After a 13-year ... is again returning to the stage to entertain his ... for concert performances, and the successful tour has been ... announced. , Visit Ticketability.com for a ... Detroit shows at fair prices. , Music fans have ...
(Date:12/19/2014)... Consilium Staffing, Your Partner in ... for Federal Health Professionals annual meeting in Washington, ... military and federal healthcare providers. , In ... Business Engagement (NVSBE) conference last week in Atlanta, ... vital solution in addressing our nation’s shortage of ...
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... 2014 (HealthDay News) -- The tragic death from "rat-bite fever" ... by the pet rodents, according to a report from the ... is a rare but potentially fatal illness that should be ... when a history of rodent exposure is reported," said a ... Intelligence Service. The case outlined in the report occurred ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3
... heart patients make use of all 36 Medicare-funded sessions, researchers ... rehabilitation sessions for elderly people with heart disease can lower ... new research finds, but fewer than one in five eligible ... of more than 30,000 Medicare patients aged 65 and older ...
... , WASHINGTON, Dec. 21 ... for passage of the amended Senate health system reform bill ... Care Act by the Senate will bring our nation close ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , "All Americans deserve affordable, ...
... , ... tradition of charitable giving at Projects In Knowledge ( www.projectsinknowledge.com ... holiday season. Over the last few months, the company has ... global organizations, all aimed at providing seasonal cheer and assistance ...
... , AVENTURA, Fla., Dec. 21 Cinergy Health ... for the consumer market, expressed its concern for the ongoing healthcare ... , "While the Senate and House healthcare bills are far from ... expanding access to affordable health coverage for all Americans," said ...
... cars shrinks and reaction times grow, study finds , MONDAY, ... themselves and others in danger as they switch their attention ... Researchers who placed young adults in a virtual driving simulator ... car ahead shrank when texting came into the mix, but ...
... to ensure protection, experts say, , MONDAY, Dec. 21 ... flu vaccine may be enough to guard children and ... the U.S. Centers for Disease Control and Prevention recommends ... H1N1 vaccine, spaced about a month apart. This is ...
Cached Medicine News:Health News:With Cardiac Rehab, More Is Better: Study 2Health News:AMA Announces Support for Passage of Senate Health Reform Bill 2Health News:AMA Announces Support for Passage of Senate Health Reform Bill 3Health News:Projects In Knowledge(R) Is Brightening the Holidays for Many in Need 2Health News:Projects In Knowledge(R) Is Brightening the Holidays for Many in Need 3Health News:Projects In Knowledge(R) Is Brightening the Holidays for Many in Need 4Health News:Cinergy Health Commentary on Senate Healthcare Vote 2Health News:Texting While Driving Raises Crash Risk Sixfold 2Health News:Single Shot of H1N1 Vaccine May Be Enough for Kids 2Health News:Single Shot of H1N1 Vaccine May Be Enough for Kids 3
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Medicine Products: